|
Aug 6
|
Seres Therapeutics: Q2 Earnings Snapshot
|
|
Aug 6
|
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
|
|
Jul 22
|
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
|
|
Jul 22
|
Seres Therapeutics Announces Leadership Transition
|
|
Jul 21
|
Seres Therapeutics, Inc.'s (NASDAQ:MCRB) top owners are individual investors with 51% stake, while 23% is held by institutions
|
|
Apr 29
|
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
|
|
Apr 17
|
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround
|
|
Mar 14
|
Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic?
|
|
Mar 14
|
Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ...
|
|
Mar 14
|
Q4 2024 Seres Therapeutics Inc Earnings Call
|
|
Mar 13
|
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
|
|
Mar 3
|
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
|
|
Oct 8
|
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value
|
|
Sep 30
|
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
|
|
Sep 26
|
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
|
|
May 13
|
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)
|
|
May 9
|
Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
|
|
May 8
|
Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates
|
|
May 8
|
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
|